Pyramidion Technology Group, Inc. (OTC: PYTG) today announces that Dr. Canasi, practicing internal medicine physician, advocate of medical marijuana, Cannabidiol (CBD), and other alternative medicines, is the latest addition to the specialist-comprised PYTG, Leafywell (Leafywell.com), Board of Advisors.
Leafywell (Leafywell.com), a subsidiary of PYTG (OTC: “PYTG”), handles the production, manufacturing, and distribution of hemp-based Cannabidiol (CBD) products such as tinctures, creams, lotions, edible candies, at both the wholesale and retail level. In the retail market, products are found at Leafywell.com, and both select retail outlets and medical offices.
The current advisory board composition of PYTG consists of multiple currently-practicing medical professionals including board-certified cardiologist and board-certified internal medicine physician, Dr. Mark Sabbota, family medicine specialist, Dr. Michael McKenzie, MD, Dr. David M. Feldbaum MD, FACS, certified in vascular surgery by the American Board of Surgery, and board-certified Surgical Neurophysiologist, Antonio A. Sama, in addition to other industry-specific board members.
The latest board addition, Dr. Javier J. Canasi, is an internal medicine physician with an active patient-treating medical practice. Dr. Canasi is an advocate of alternative medicine including the both hemp-based CBD products, marijuana-based CBD, and medicinal marijuana, when appropriate for the particular medical condition.
Dr. Canasi, when asked, “How do you view the role of CBD in medical treatment plans?”, Dr. Canasi responded candidly, “I appreciate all types of medicine that help patients achieve their treatment goals and we are fortunate to live in a world in which we have options, healthy options. I am a strong advocate of incorporating CBD into a treatment, when appropriate, and in some cases, it is used as a stand-alone treatment and in others I suggest to my patients a mix of CBD along with a regimen of medicinal marijuana or other medicines. CBD can be incorporated to manage a selection of types of pain, including chronic pain.”
Dr. Canasi’s medical practice offers for purchase a selection of Leafywell (Leafywell.com) products. The wide range of Leafywell products available at Dr. Canasi’s office include tinctures ranging from low-concentration compositions to high-concentration compositions, edible gummy candies, lotions, creams, and others.
“I carry the full Leafywell product line for all my patients. For some patients, I recommend a tincture and for others I prefer they begin with pre-measured edible gummy candies. That said, the products I recommend to my individual patients depends on a variety of factors. Leafywell creams and lotions can also be an option depending on individual circumstances and medical conditions. Leafywell can be both a stand-alone option in a treatment plan as well as in tandem with other products and medications.”, responded Dr. Canasi, regarding his experience with Leafywell products.
Carlos Hurtado, CEO of PYTG, when asked to share his thoughts about Dr. Canasi’s most recent addition to the PYTG Advisory Board, posited, “We are thrilled to now have Dr. Canasi serving on our board of advisors alongside our existing medical specialists and we feel he has the knowledge of CBD products, CBD-containing treatment plans along with patient responses, and medical marijuana, that truly benefits our company. Dr. Canasi is consummate medical professional committed to providing optimal treatment to his patients and we are pleased that he has decided to serve in this advisory capacity. The fact that Dr. Canasi has our Leafywell line of products available to his patients in his medical office is a testament to his confidence in Leafywell.”
CBD has been said to be a topic of considerable discussion in the medical community, the research community, and the patient community. CBD research has provided evidentiary findings demonstrating its potentially beneficial symptomatic relief for vast range of ailments, including rheumatoid arthritis, diabetes, alcoholism, post-traumatic stress disorder, epilepsy, antibiotic-resistant infections, neurological disorders, chronic pain, and muscular dystrophy, among others.
About Pyramidion Technology Group, Inc
Pyramidion Technology Group, Inc. (“PYTG” or the “Company”) is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.
Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our
overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance
on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/PYTG/filings.
4350 Oakes Rd
Davie, FL 33314